1-17 of 17
Ralph E. Parchment
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller, Barry C. Johnson, Larry Anderson, Larry Rubinstein, Brandon Miller, Deborah F. Wilsker, Katherine V. Ferry-Galow, Richard Piekarz, Jennifer Zlott, Murielle Hogu, Lamin Juwara, Julia Krushkal, Mariam Konaté, Alida Palmisano, Yingdong Zhao, Jerry Collins, Ralph E. Parchment, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-3049
Published: 16 April 2025
View articletitled, A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3834–3844.
https://doi.org/10.1158/1078-0432.CCR-21-0329
Published: 15 July 2021
View articletitled, Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Open the PDF for Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers

Deborah F. Wilsker, Allison M. Barrett, Angie B. Dull, Scott M. Lawrence, Melinda G. Hollingshead, Alice Chen, Shivaani Kummar, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 3084–3095.
https://doi.org/10.1158/1078-0432.CCR-18-2523
Published: 15 May 2019
View articletitled, Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
Open the PDF for Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers in another window
Includes: Supplementary data
Journal Articles

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Jenna H. Burton, Christina Mazcko, Amy LeBlanc, Joseph M. Covey, Jiuping Ji, Robert J. Kinders, Ralph E. Parchment, Chand Khanna, Melissa Paoloni, Sue Lana, Kristen Weishaar, Cheryl London, William Kisseberth, Erika Krick, David Vail, Michael Childress, Jeffrey N. Bryan, Lisa Barber, E.J. Ehrhart, Michael Kent, Timothy Fan, Kelvin Kow, Nicole Northup, Heather Wilson-Robles, Joseph Tomaszewski, Julianne L. Holleran, Miguel Muzzio, Julie Eiseman, Jan H. Beumer, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5830–5840.
https://doi.org/10.1158/1078-0432.CCR-18-1498
Published: 03 December 2018
View articletitled, NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Open the PDF for NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Apurva K. Srivastava, Melinda G. Hollingshead, Jennifer Weiner, Tony Navas, Yvonne A. Evrard, Sonny A. Khin, Jiuping Jay Ji, Yiping Zhang, Suzanne Borgel, Thomas D. Pfister, Robert J. Kinders, Donald P. Bottaro, W. Marston Linehan, Joseph E. Tomaszewski, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (14): 3683–3694.
https://doi.org/10.1158/1078-0432.CCR-15-2323
Published: 14 July 2016
View articletitled, Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Open the PDF for Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3227–3237.
https://doi.org/10.1158/1078-0432.CCR-15-0652
Published: 30 June 2016
View articletitled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Apurva K. Srivastava, Soumya Jaganathan, Laurie Stephen, Melinda G. Hollingshead, Adam Layhee, Eric Damour, Jeevan Prasaad Govindharajulu, Jennifer Donohue, Dominic Esposito, James P. Mapes, Robert J. Kinders, Naoko Takebe, Joseph E. Tomaszewski, Shivaani Kummar, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 1000–1010.
https://doi.org/10.1158/1078-0432.CCR-14-3156
Published: 14 February 2016
View articletitled, Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Open the PDF for Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use in another window
Includes: Supplementary data
Journal Articles

Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations

Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2578–2586.
https://doi.org/10.1158/1078-0432.CCR-14-0476
Published: 14 May 2014
View articletitled, Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
Open the PDF for Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations in another window
Journal Articles

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Jiuping Ji, Robert Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1726–1734.
https://doi.org/10.1158/1078-0432.CCR-11-2821
Published: 14 March 2012
View articletitled, A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5447–5457.
https://doi.org/10.1158/1078-0432.CCR-09-3076
Published: 14 November 2010
View articletitled, Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
Open the PDF for Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity in another window
Includes: Supplementary data
Journal Articles

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (18): 4532–4542.
https://doi.org/10.1158/1078-0432.CCR-10-0523
Published: 14 September 2010
View articletitled, Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Open the PDF for Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers in another window
Journal Articles

Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

Lihua H. Wang, Thomas D. Pfister, Ralph E. Parchment, Shivaani Kummar, Larry Rubinstein, Yvonne A. Evrard, Martin E. Gutierrez, Anthony J. Murgo, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 1073–1084.
https://doi.org/10.1158/1078-0432.CCR-09-2799
Published: 01 February 2010
View articletitled, Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
Open the PDF for Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells in another window
Includes: Supplementary data
Journal Articles

Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

Robert J. Kinders, Melinda Hollingshead, Sonny Khin, Larry Rubinstein, Joseph E. Tomaszewski, James H. Doroshow, Ralph E. Parchment, the National Cancer Institute Phase 0 Clinical Trials Team
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6877–6885.
https://doi.org/10.1158/1078-0432.CCR-08-0214
Published: 03 November 2008
View articletitled, Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
Open the PDF for Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts in another window
Includes: Supplementary data
Journal Articles

Designing Phase 0 Cancer Clinical Trials

Anthony J. Murgo, Shivaani Kummar, Larry Rubinstein, Martin Gutierrez, Jerry Collins, Robert Kinders, Ralph E. Parchment, Jiuping Ji, Seth M. Steinberg, Sherry X. Yang, Melinda Hollingshead, Alice Chen, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3675–3682.
https://doi.org/10.1158/1078-0432.CCR-07-4560
Published: 16 June 2008
View articletitled, Designing Phase 0 Cancer Clinical Trials
Open the PDF for Designing Phase 0 Cancer Clinical Trials in another window
Journal Articles

Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient

James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3658–3663.
https://doi.org/10.1158/1078-0432.CCR-07-4562
Published: 16 June 2008
View articletitled, Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient
Open the PDF for Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient in another window
Journal Articles

The Investigational New Drug XK469 Induces G2-M Cell Cycle Arrest by p53-dependent and -independent Pathways

Zhenhua Ding, Ralph E. Parchment, Patricia M. LoRusso, Jun-Ying Zhou, Jun Li, Theodore S. Lawrence, Yi Sun, Gen Sheng Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (11): 3336–3342.
Published: 01 November 2001
View articletitled, The Investigational New Drug XK469 Induces G2-M Cell Cycle Arrest by p53-dependent and -independent Pathways
Open the PDF for The Investigational New Drug XK469 Induces G2-M Cell Cycle Arrest by p53-dependent and -independent Pathways in another window
Journal Articles

Cytotoxic Chemotherapy Regimens That Increase Dose per Cycle (Dose Intensity) by Extending Daily Dosing from 5 Consecutive Days to 28 Consecutive Days and Beyond

Kristan A. Keyes, Beatriz Albella, Patricia M. LoRusso, Juan A. Bueren, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2474–2481.
Published: 01 June 2000
View articletitled, Cytotoxic Chemotherapy Regimens That Increase Dose per Cycle (Dose Intensity) by Extending Daily Dosing from 5 Consecutive Days to 28 Consecutive Days and Beyond
Open the PDF for Cytotoxic Chemotherapy Regimens That Increase Dose per Cycle (Dose Intensity) by Extending Daily Dosing from 5 Consecutive Days to 28 Consecutive Days and Beyond in another window